All posts by imreal

Explore the Trippy World of Hallucinogens at PAINWeek 2022, on Friday, September 9, at The Cosmopolitan of Las Vegas


PAINWeek Pain Management Conference, September 6-9

Psychedelic medicine has been stigmatized and isolated from us for too long. Now is the time to revolutionize care for addiction, pain, and mental health using whatever tools we have, and psychedelic medicine is the most promising potential weapon in this battle.

“Psychedelic medicine has been stigmatized and isolated from us for too long. Now is the time to revolutionize care for addiction, pain, and mental health using whatever tools we have, and psychedelic medicine is the most promising potential weapon in this battle,” states Dr. Eugene Vortsman, who will be presenting at the PAINWeek National Conference, September 6-9, at The Cosmopolitan of Las Vegas, during the Psychedelics Track on Friday, September 9.

His presentation is Purple Haze: Mysticism & Science of Psychedelics, about which Dr. Vortsman said, “to best understand the true potential of these powerful medicines it is important to understand the cultural and scientific history of hallucinogenics leading to the current landscape for future growth. Come on this psychedelic journey through time, space, and science. Together, we will explore the trippy world of hallucinogens.” Eugene Vortsman, DO, FACEP, is Clinical Director of Addiction Medicine and Disease Management at Northwell Health, Long Island Jewish Medical Center in Queens, NY.

“The psychological mechanism and insight gained during nonordinary states of consciousness is as important as the biological mechanism of the medication,” says Dr. Michelle Weiner. Her presentation is K Especial: The Biopsychosocial Model of Personalizing Ketamine for Pain Management. She continued, “practicing medicine during an opioid epidemic and mental health crisis has challenged physicians to evaluate if we are treating chronic physical and emotional pain effectively. Ketamine’s dose, route of administration, and setting can be personalized and integrated into the treatment plan.” Michelle Weiner DO, MPH, is an Integrative Pain Management Physician at the Spine and Wellness Centers of America in Miami, Florida.

Dr. Sanjey Gupta’s presentation, The Glass Bead Game: Harm Reduction and Its Potential Impact on the Opioid Crisis, will discuss the combination of programs, policies, and practices that aim to reduce the negative social, health, and legal implication associated with drug use. He commented, “we are pleased that PAINWeek is a leading source of education in harm reduction, as these initiatives are grounded in social justice and human rights.” Sanjey Gupta, MD, MBA, is a Professor of Emergency Medicine at the Zucker School of Medicine at Hofstra/Northwell Health, Rockville Centre, NY.

PAINWeek will present 90+ CME/CE credit hours in tracks such as Behavioral Pain Management, Chronic Pain Syndromes, Health Coaching, Interventional and Integrative Pain Management, Medical/Legal, Neurology, Physical Therapy, and Pharmacotherapy. Master Classes, Special Interest Sessions, and sponsored courses complement the agenda, along with tracks presented by The American Society of Interventional Pain Physicians and the International Pelvic Pain Society.

For more information, click PAINWeek or go to painweek.org.

PAINWeek accreditation provided by Global Education Group:

Global Education Group focuses on producing partnership-based CME for healthcare practitioners. The Global team works with a select group of medical education companies, associations, academic institutions, and healthcare facilities to develop and accredit live healthcare conferences and workshops as well as online activities. With each partnership or joint providership, Global brings accreditation expertise, project management excellence and grant funding intelligence. Based in Littleton, Colo., Global has accreditation with commendation from the ACCME and accredited with distinction from the ANCC. Global also holds accreditations to offer continuing education for nurse practitioners, pharmacists, dietitians, dentists, and psychologists. Global is a division of Ultimate Medical Academy.

###

Share article on social media or email:

U.S. Dermatology Partners Launches New Research Institute


U.S. Dermatology Partner Clinical Research Institute

U.S. Dermatology Partner Clinical Research Institute

“Our goal is to increase the treatments that our clinical team can incorporate into their practices and provide our patients with advanced dermatologic care that can help improve their health and quality of life,” said CEO of U.S. Dermatology Partners, Paul Singh.

With skin diseases affecting one in three Americans at any given time, U.S. Dermatology Partners, one of the leading and largest dermatology groups in the country, caring for more than 1.5 million patients each year, announced today that they will be launching their Research Institute. This new program will increase access to otherwise unavailable treatments for various impactful dermatological diseases including, but not limited to psoriasis, atopic dermatitis, prurigo nodularis, hidradenitis suppurativa, bullous pemphigoid, congenital ichthyoses, and non-melanoma skin cancers.

The U.S. Dermatology Partners Research Institute is currently involved in three types of clinical trials: observational studies, interventional, and device trials. The goal of these clinical trials is to assist in the discovery of more safe and accurate diagnostic testing capabilities, prognostic testing capabilities, and patient-centered therapeutic options. This new program will facilitate breakthroughs in the science of prognosis and individualized ‘precision’ medicine, allowing for a better understanding of disease characteristics, and treatments at the patient-specific level.

“Our goal is to increase the treatments that our clinical team can incorporate into their practices and provide our patients with advanced dermatologic care that can help improve their health and quality of life,” said Chief Executive Officer of U.S. Dermatology Partners, Paul Singh. “We’re proud to spearhead this program that’ll help us further our mission while advancing the field of medical dermatology.”

Led by Board-Certified Dermatologist, Dr. Lindsay Ackerman, the Research Institute is centrally supported by an experienced team enabling the healthcare organization to streamline trial startup and conduct multi-site trials. The organization’s clinical trial management capabilities include reporting via a centralized electronic database to allow trial sponsors to access real-time data from the studies.

“Providing access to meaningful interventions that would not otherwise be available for dermatologic diseases of grave consequence continues to be an exciting aspect of our clinical care,” said Dr. Lindsay Ackerman, Board-Certified Dermatologist. “Not only is it incredibly rewarding to facilitate substantial improvement in disease, but in doing so we are also breaking down barriers to care. Being able to deliver these options, while allowing for the development of scientific proof required to ultimately reach millions of others, is both a privilege and responsibility we don’t take lightly.”

The research centers will collaborate with innovative pharmaceutical companies through industry-sponsored clinical studies that involve new treatment agents as well as available medications. Through the Research Institute, U.S. Dermatology Partners will leverage their vast network of patients, clinical team, and board-certified physicians to advance the field of medical dermatology. U.S. Dermatology Partners has participated in 50 trials in 2022, and currently, there are 35 active trials across the organization.

To learn more about the ongoing clinical trials at U.S. Dermatology Partners visit clinicaltrials.usdermatologypartners.com

About U.S. Dermatology Partners

U.S. Dermatology Partners is one of the largest dermatology practices in the country, caring for more than 1.5 million patients each year with nearly 100 locations across eight states. U.S. Dermatology Partners patients have access to general medical, surgical, and cosmetic skin treatments through its coordinated care network and benefit from the practice’s strong dermatology subspecialty thought leaders and medical advisory board. To be the best partner to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery. To learn more, visit usdermatologypartners.com.

Share article on social media or email:

Concelor’s newly released “A Glimpse of Heaven” is a thought-provoking discussion of encounters with God via dreams, visions, and prayer


News Image

“A Glimpse of Heaven”: a potent example of God’s commitment to creation and one’s connection with the celestial. “A Glimpse of Heaven” is the creation of published author Concelor.

Concelor shares, “A Glimpse of Heaven is an inspirational book that highlights some of the revelations of God through dreams and visions and the study of God’s Word. This book also seeks to help those who are attempting to understand the human prospect with the mysteries of God. What’s more, it aims to give one an idea of the process one has to endure for their relationship with God. It also recognizes some of those who are in the public arena that work every day with the intention of introducing the world to Jesus Christ in spite of the scrutiny and the price they pay while explaining how Christ provides an alternative for the life of depression, abuse, neglect, chaos, despair, and hopelessness by helping people gain a life of peace, joy, happiness, and purpose. It also aims to teach someone how important they are to the creator of the universe.”

Published by Christian Faith Publishing, Concelor’s new book will challenge and encourage readers in their spiritual journey.

Concelor shares in hopes of bringing comfort and encouragement to those in need of reassurance in their role within God’s plan.

Consumers can purchase “A Glimpse of Heaven” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “A Glimpse of Heaven,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Robert L. Porter, Jr.’s newly released “Life, Love and God Viewed Through the Porthole” is an enjoyable collection of poetry inspired by life, faith, and love


News Image

“Life, Love and God Viewed Through the Porthole”: a captivating selection of deeply personal poetry. “Life, Love and God Viewed Through the Porthole” is the creation of published author Robert L. Porter, Jr., a retired businessman who was born and raised in Atlanta, Georgia, graduated from Georgia Tech, served over five years in the USAF, and spent many years in the computer industry.

Porter shares, “Porthole was an early life nickname that has stuck with me for over seventy-five years. I had joined the US Navy Reserve and became an avid competitive sailor. My poetry reflects my views and visions on life and love and God. So I have used Porthole to identify those poetic literary efforts.”

Published by Christian Faith Publishing, Robert L. Porter, Jr.’s new book will take readers on a guided journey thought the author’s key life experiences.

Porter’s carefully structured poems will encourage reflection and draw at the heartstrings as readers are offered a personal window into the moments that have shaped his life’s journey.

Consumers can purchase “Life, Love and God Viewed Through the Porthole” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Life, Love and God Viewed Through the Porthole,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Tragic Effects of Leading with Wounds and a Surprising Solution” is an encouraging message of God’s healing promise


News Image

“Gallant Fool: Tragic Effects of Leading with Wounds and a Surprising Solution”: a powerful message of God’s grace. “Gallant Fool: Tragic Effects of Leading with Wounds and a Surprising Solution” is the creation of published author Larry Cooney, a dedicated husband and father who, after planting (starting) a church with the Assemblies of God, served as a director in three Gospel mission agencies—Bread of Life Mission in Seattle, cofounder of Kitsap Rescue Mission in Bremerton, Washington, and Central Coast Rescue Mission in Santa Maria, California. He has started Leading in Joy with its curriculum, Skiltegrity, to leverage his three decades of experience in Christian ministry to help young leaders thrive in vocational ministry.

Cooney shares, ““My solution was to keep marching forward, a gallant fool. I was most angry at this fool’s seemingly unstoppable march.”

“Gallant Fool examines the painful subject of carrying emotional wounds into Christian leadership. It follows the author’s life in ministry and toxic relationship with shame and anxiety through starting a church, peaching and leading a congregation, managing staff members at Gospel missions, and working with authority figures like board members, a CEO, and other pastors.

“Ministry requires faith; shame and anxiety corrode it. Living in a paradox this way is a burden. The author’s burdens followed him into his faith in Christ and stayed with him through his career and marriage. He now realizes that for years, he believed and preached a Christian message that often worked against bringing peace and resolution.

“The book contains sixteen short essays and ten chapters to describe carrying this burden and an eventual resolution, which the author describes as Christ’s deliverance through a process of awareness, acknowledgment, and acceptance.

“Cooney makes the point that Jesus offers relief to anyone carrying burdens, and he delivers his children regardless of the nature, duration, and magnitude of the burden; that’s because God delivers us by grace through faith, a message that is familiar and at the same time elusive for its simplicity and refusal to credit anyone for a successful deliverance, except God. Gallant Fool offers hope by putting the spotlight on where it belongs: God and his grace.”

Published by Christian Faith Publishing, Larry Cooney’s new book will bring readers a thought-provoking and comforting message.

Cooney draws from personal experience to bring readers a helpful opportunity to grow, recover, and heal.

Consumers can purchase “Gallant Fool: Tragic Effects of Leading with Wounds and a Surprising Solution” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Gallant Fool: Tragic Effects of Leading with Wounds and a Surprising Solution,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Bragg Canna of Mississippi, LLC (Bragg Canna) receives approval to provide medical cannabis to licensed patients in Mississippi


Bragg Canna Logo

As of August, 2022, Bragg Canna of Mississippi, LLC (operating out of Canton, MS) has been granted license approvals to provide medical cannabis to licensed patients in the state of Mississippi. Bragg Canna will initially launch a dispensaries in Pearl and Tupelo, MS.

As of August, 2022, Bragg Canna of Mississippi, LLC (Bragg Canna) is approved by the state of Mississippi as a licensee for the cultivation, processing, and dispensing of medical cannabis. Bragg Canna will cultivate and process medical cannabis in Canton, Mississippi and announce two initial dispensary locations in Tupelo and Pearl. The Pearl location is just across the river from the state capital of Jackson, MS and other dispensary locations are expected to be announced in upcoming months.

Dennis Bragg of Bragg Farms is the leader of Bragg Canna. Dennis, alongside his family, cultivates more than 10,000 acres in Tennessee, Alabama, and Louisiana. Bragg Farms is synonymous in the South with the finest crops of cotton, wheat, soybeans, and corn. Mr. Bragg is highly regarded in the agricultural community throughout the Southeastern United States for his innovations in irrigation and other agricultural advancements as well as his civic and community service.

Mr. Bragg describes the personal value of this opportunity to help patients across the state of Mississippi: “What this license does is it allows me to come in direct contact with patients and caregivers just like myself that I wouldn’t have the chance to serve otherwise. I have had people help me and my family in the past and now I will be able to help others. I’m grateful to have this opportunity.”

Mr. Bragg attended Auburn University and received a Building Science degree from the School of Architecture, before returning home to North Alabama to focus on operating and managing Bragg Farms. With his vision and support from his family, Mr. Bragg designed and built the largest irrigation systems in the southeast. The most recent irrigation system project won Alabama’s 2017 BuildSouth Award. The successfully consistent irrigated crops, robust supply chain, and years of experience have allowed Bragg Farms to supply numerous Fortune 500 companies, with agricultural products necessary to make their businesses thrive.

In 2019, Mr. Bragg began growing and processing over 3,000,000 CBD-rich hemp plants through Alabama’s pilot program to introduce the use of cannabis to those seeking a way to ease their suffering. Through a generational reputation of integrity and agricultural success, Mr. Bragg has built Bragg Canna to bring consistent, high quality, medical grade cannabis to comfort patients in need of relief.

Mr. Bragg sees the similarities between the newer cannabis crops and the more traditional crops his family has been growing for generations: “As a farm family, we have spent generations teaching ourselves how to grow food to build and sustain our bodies. Now we will take that knowledge and grow medicine to heal and comfort our bodies.”

Mr. Bragg is joined by Lewis Swarts (COO) who brings extensive large-scale agricultural, process control, and cannabis industry experience to Bragg Canna to provide high-quality medical cannabis to patients in the state of Mississippi. Mr. Swarts has spent time as the National Directory of Operational Excellence and Vice President of Operations of the largest value-added produce/vegetable company in the world, servicing various Fortune 20 companies. Mr. Swarts has leveraged his agricultural business expertise within the cannabis and hemp industry with numerous executive roles and board positions for market-leading public cannabis operators and private global leaders in industrial hemp. His proficiency from cultivation to dispensing has added value and standardized growth to the dynamic cannabis sector and has a track record of success in new ventures. While utilizing his experience in operating large scale operations: he is focused on building medical cannabis companies that are patient-focused, local, and of the highest standards.

While Bragg Canna’s collective business and industry leadership experience is extensive, perhaps more robust is their goal to deliver a patient experience that is second-to-none and tailored to patient and healthcare provider needs.

When initially founding Bragg Canna, the goal from the outset was clear: communicate to patients and healthcare providers that a highly-professional and well-qualified agricultural team (with additional background in cannabis cultivation and production operations) is responsible for growing and processing their medical cannabis from seed-to-sale. Bragg Canna’s leadership and collective experience helps ensure the highest quality products as well as the most welcoming and educational experience will be provided to new and experienced medical cannabis patients. Bragg Canna’s leadership recognizes the importance of providing consistent, safe, and effective medication on which patients and healthcare providers can rely.

“We believe there are clear advantages in having farmers with a deep well of experience in safely and effectively growing a food supply to shift into growing medical cannabis. The attention to detail necessary to ensure the medication patients put into their bodies is safe, clean, and beneficial is an area we are confident we are able to excel, because we have already done so in a similar manner for generations with food,” Mr. Bragg says.

Bragg Canna’s initial cultivation and warehouse space is designed and built in an effort to ensure they can effectively service patients across the state of Mississippi.

Bragg Canna’s logo depicts the Caladrius, a mythical bird derived from Roman mythology that is said to draw a person’s sickness or suffering into itself and fly it up into the sun.

Mr. Bragg defines the importance in selecting a brand image that portrays more to patients than simply a cannabis leaf: “In choosing Caladrius to represent Bragg Canna, it was more about what cannabis does than what it is. Everyone has their thought about what cannabis is, but what it does is more singular. When I saw an image of this mythical bird standing on the chest of a child drawing out their sickness with its stare, I knew at that moment that was a clear allegory of what cannabis does and that we needed such an image to help patients understand how we view their medical journey: a journey of healing and restoration.”

Patients and healthcare providers can learn more about Bragg Canna by visiting their website at braggcanna.com or by calling their corporate offices at 256-47-CANNA (256-472-2662).

Share article on social media or email:

AI Metrics, an AI Medical Imaging Technology Startup, Announces New Chief Medical Officer and CEO


News Image

​​”I am honored to lead this innovative company that is delivering solutions to radiologists who work on important issues such as saving lives and working with advanced cancers,” said Bob Jacobus, CEO, AI Metrics.

AI Metrics, an early stage radiology software company, announces changes to its executive leadership team, naming Dr. Andrew Smith as Chief Medical Officer and appointing Bob Jacobus as CEO.

AI Metrics, launched in 2019 by Jacobus, Paige Severino, and radiologist and researcher Dr. Smith is developing software to more accurately assess cancer treatment effectiveness. The founders set out to leverage augmented intelligence in innovative imaging software solutions, improve radiology workflows, quantitative metrics, and reporting in clinical practice and clinical trials.

Dr. Smith, the Company’s initial CEO, will take on the newly created role of Chief Medical Officer while continuing his role as Chairman of the Board. Dr. Smith is currently a Radiologist and Oncologic Imager at the University of Alabama at Birmingham. He is Vice Chair of Clinical Research, Chief of Body CT, and is also the Clinical Director of AI at the University’s Heersink Institute of Biomedical Innovation.

“I am excited to take on the role of Chief Medical Officer at AI Metrics, where I will be able to focus on the clinical aspects, the necessary research and new and innovative advancements needed in radiology and cancer treatment evaluation,” said Dr. Smith. “AI Metrics was created to utilize advanced technologies to help standardize reporting with greater inter-observer agreement, while decreasing variations in impressions – making it more useful and easier for oncologists to interpret data and information for their patients.”

Jacobus was the company’s initial COO and has more than 20 years of experience in founding, investing in and raising capital for startups. He is an experienced financial professional, with significant industry experience in investment banking, early-stage ventures, financial management, new business development, engineering, operations, and manufacturing. Jacobus also has deep experience in the biotech, medical products manufacturing, software, transportation and insurance sectors.

​​”I am honored to lead this innovative company that is delivering solutions to radiologists who work on important issues such as saving lives and working with advanced cancers,” said Jacobus. “My role as CEO is to lead AI Metrics as it helps solve real radiology pain points using AI technologies to improve accuracy, consistency, and efficiency in radiology.”

To learn more about AI Metrics, and its executive leadership team, please visit, https://www.aimetrics.com/

About AI Metrics

AI Metrics was founded by a radiologist to help radiologists who work on advanced cancers be more productive. The AI Metrics solution is helping radiologists at multiple healthcare organizations save time and make consistently precise readings easier to achieve. This makes it simpler and less and cumbersome to adopt standardized cancer workflows. This helps in delivering accurate, standardized readings and decreased variation in care. Moreover, AI Metrics’ graphical output is more useful and easier to interpret for oncologists and their patients.

Share article on social media or email:

Northeast Delta HSA releases Fiscal Year 2022 Annual Impact Report


Northeast Delta HSA releases Fiscal Year 2022 Annual Impact Report

Northeast Delta HSA releases Fiscal Year 2022 Annual Impact Report

“NEDHSA took on a ground-breaking initiative last year through its Rise Above Stigma work, and this report will show that lives have been changed,” Shipp said.

Northeast Delta Human Services Authority (NEDHSA) announces its Annual Impact Report for the Fiscal Year 2021-2022 (FY22), a document highlighting the agency’s service in fulfilling its mission to Northeast Louisiana.

NEDHSA Board of Directors Chairman Michael K. Shipp said he expresses his support and gratitude for the “innovation, creation of partnerships, and development of evidence-based practices in fulfilling the agency’s mission.”

“NEDHSA took on a ground-breaking initiative last year through its Rise Above Stigma work, and this report will show that lives have been changed,” Shipp said. “The agency carefully and compassionately engaged the region’s vulnerable populations in non-traditional ways through psychodramas, hip-hop music, and its mobile app. We are proud to serve in the capacity we do in supporting the work of the executive director, the staff, contractors, and many others who work to make NEDHSA what it is.”

The report reveals NEDHSA’s work in its 12-parish service area, where it delivered outpatient behavioral health services to more than 1,400 outpatient clients, providing more than 25,500 billable and non-billable services. In working with its funded Network of Care partnerships, NEDHSA served 826 clients in inpatient facilities.

NEDHSA Executive Director Dr. Monteic A. Sizer said, “the agency found that it must continue to meet the needs of the region’s people consistently, respectfully, and where they are.”

“As we continue to provide prevention and clinical services to individuals diagnosed with mental illnesses, addictive and substance use disorders, and developmental disability challenges, we remain committed to working across societal issues such as race, class, poverty, geographic isolation, and health stigma.” Dr. Sizer said. “Our annual report shows the value of our integrated health model and how it works to improve population health outcomes in our region.”

The annual report reveals that NEDHSA reviewed 580 applications for developmental disability eligibility, provided oversight, including Statement of Approval, to 339 participants, and provided Act-378 Program Services to 625 individuals. NEDHSA also provided valuable prevention and wellness services and education in FY2022, including completing 1,000 SYNAR compliance checks, distributing 1,382 NARCAN kits, and disseminating substance abuse prevention and treatment information to more than 1,154,999 citizens.

NEDHSA’s Director of Behavioral and Primary Health Analytics, Dr. Dependra Bhatta, said, “the agency’s integrated health approach is providing greater access to critical services needed by the most vulnerable in the region.”

“Particularly in our behavioral health clinics: a higher number of Black clients and male clients were diagnosed with schizophrenia spectrum & other psychotic disorders,” Dr. Bhatta said. “For White clients and female clients, depressive disorders were most common. Anxiety, bipolar and related disorders, schizophrenia spectrum and other psychotic disorders, and depressive disorders were higher in the 36-50 years age group.”

The report also shows NEDHSA’s client satisfaction and outcomes for FY2022, indicating high client satisfaction rates, with 98% of clients stating they would continue NEDHSA services and would recommend our clinics and services to their family, friends, and others. More than 83% of surveyed existing adult clients seen in NEDHSA outpatient clinics reported improved functioning, and over 80% of adult clients reported positive treatment outcomes and positive social connectedness. More than 70% of adult clients in FY2022 reported reduced alcohol/drug use.

Dr. Sizer added, “We will continue to innovate, integrate, form committed partnerships, be a catalyst for, and inspire those we serve. We understand the importance of our work in the lives of so many individuals, families, and communities in Louisiana’s Delta.”

To view the annual report – click here: https://bit.ly/NEDHSAFY22AnnualReport

Share article on social media or email:

NY Vision Group Joins Distinguished OCLI Vision Ophthalmology Practice to Ensure Continued Focus on High-Quality Patient Care


“NY Vision Group is a multi-specialty practice focused on bringing advanced technology and innovative surgical techniques to their patients. This group of highly talented doctors is well poised to help us achieve our future goals” says Tom Burke, SVP’s CEO.

Once again, OCLI Vision is expanding its team of exceptionally talented eye care specialists with the acquisition of NY Vision Group. OCLI Vision, a multi-practice ophthalmology group located in the Northeast, is committed to expanding access to advanced eye care services throughout the region and supporting eye care specialists through innovative programs. NY Vision Group provides cataract, LASIK, glaucoma, retina, and uveitis services from their offices in Tribeca (Manhattan), Richmond Hill (Queens), and Bushwick (Brooklyn), NY.

OCLI Vision is a leading ophthalmology practice whose growth is supported by the management and administrative services of Spectrum Vision Partners (SVP), an organization serving many of the top ophthalmology groups and ambulatory eye surgery centers in New York, New Jersey, Connecticut, Pennsylvania and West Virginia. NY Vision Group is Spectrum’s 21st affiliation since 2017.

“2021 was a growth-filled year for OCLI Vision and SVP, and we are delighted to start this third quarter of 2022 with another acquisition,” says Tom Burke, SVP’s CEO. “NY Vision Group is a multi-specialty practice focused on bringing advanced technology and innovative surgical techniques to their patients. This group of highly talented doctors is well poised to help us achieve our future goals. We’re delighted they are joining the team and look forward to many successful endeavors.”

Joining OCLI Vision from NY Vision Group is Harry Koster, MD and his talented group of eye care doctors and surgeons detailed here: nyvisiongroup.com.

The doctors at NY Vision Group have a wealth of experience providing the highest standards of care to their patients. The group’s mission is to preserve vision and treat disease early using the best detection technologies available and the best medical and surgical care for patients. NY Vision Group’s doctors have trained at top institutions and boast reputable affiliations, making this group of eye care specialists the perfect choice for eye care in New York City, Queens and Brooklyn.

“We’re thrilled to be joining the OCLI Vision Group,” noted Harry Koster. “Throughout our history of providing high-quality services to the communities of New York City, we have built an incredibly talented team of premiere eye care specialists. Joining OCLI Vision gives us the opportunity to continue to further our education, utilize the most advanced technology and surgical techniques, and learn from a group of experienced professionals. We’re looking forward to our future together.”

For more information about OCLI Vision and Spectrum Vision Partners, please contact:

Tom Burke

Chief Executive Officer

tburke@spectrumvisionpartners.com

Greg Wappett

Chief Development Officer

gwappett@spectrumvisionpartners.com

About OCLI Vision

Founded in 1997, OCLI Vision (http://www.ocli.net) is one of the leading ophthalmology practices in the United States. The practices of OCLI Vision offer eye care services at locations throughout Connecticut, New Jersey, New York, Pennsylvania, and West Virginia. OCLI Vision is led by a large group of highly skilled ophthalmologists and optometrists in each major sub-specialty of eye care who provide comprehensive eye care services, including treatment for cataracts, corneal disease, glaucoma, retinal disease, oculoplastics, refractive surgery, and neuro-ophthalmology.

About Spectrum Vision Partners

Spectrum Vision Partners (SVP) (http://www.spectrumvisionpartners.com) is a leading management services organization, serving the ophthalmology sector. With nearly 1,300 employees providing world-class practice management and administrative solutions to a network of nationally renowned, multi-specialty ophthalmologists in New York, New Jersey, Connecticut, Pennsylvania and West Virginia, SVP supports over 40 clinic locations, five state-licensed ambulatory surgery centers, and over 110 surgeons, doctors and other medical professionals. SVP provides a comprehensive set of business support functions, including billing and collections, credential services, marketing, physician recruitment, ASC development, financial and accounting services, benefits and payroll management and information technology. The company’s corporate service center is located at 825 East Gate Boulevard, Suite 111, Garden City, NY 11530.

About Blue Sea Capital

Blue Sea Capital (http://www.blueseacapital.com) is a private equity firm based in West Palm Beach, Florida, that invests in growth-oriented lower middle market companies valued up to $250 million. The firm has more than $750 million in assets under management and invests across three industry verticals: aerospace & defense, healthcare, and industrial growth. Blue Sea Capital’s strategy is to partner with talented managers and differentiated companies, typically as the first or second institutional investor, and deliver strategic and operational value-add that drives growth acceleration, industry outperformance and business transformation.

Share article on social media or email:

ClinOne Announces Participation at the Rocky Mountain Life Sciences Investor and Partnership Conference


News Image

We continue to scale our business at a rapid pace as sponsors, CROs and research institutions recognize that our adaptive experiences platform makes it easier than ever to achieve and maintain higher compliance in global clinical trials. =Rob Bohacs, ClinOne Founder and Chief Solutions Officer

ClinOne, the Adaptive Experience platform for clinical trial participants, is among a select number of companies invited to present at the Rocky Mountain Life Sciences Investor & Partnering Conference (website), September 13-14, 2022 in Vail, Colorado.

“We’re honored to be invited to participate once again in this important conference to share our remarkable story with investors and industry associates,” ClinOne Founder and Chief Solutions Officer Rob Bohacs (LinkedIn) said. “We continue to scale our business at a rapid pace as sponsors, CROs, and research institutions recognize that our adaptive experiences platform makes it easier than ever before for patients and caregivers to enroll, stay engaged, and maintain higher compliance in global clinical trials.”

The Rocky Mountain Life Sciences Investor & Partnering Conference brings together high-profile investors and representatives from life sciences companies in the Rocky Mountain region to learn about new breakthroughs from emerging life sciences companies like ClinOne. The Conference is organized by the Colorado BioScience Association.

About ClinOne

ClinOne provides adaptive experiences for participants in clinical trials. By offering choice to patients, caregivers, and site staff, our technology makes it easier to stay active, compliant, and comfortable in a trial – thereby expanding enrollment access, reducing drop-out rate, and shortening conduct timelines. Our true single platform features solutions for local HCP trial awareness, remote and on-site eConsent, Uber Health, medication adherence, and a DCT portal. ClinOne stands alone with the industry’s fastest implementation (average 2-4 weeks), cost-efficient scale, and seamless API integrations for complex therapeutic areas such as Oncology, CNS, and Rare Disease in over 60 languages. To learn why more than 55 sponsors and CROs trust ClinOne in 100+ currently active studies to connect, inform, and empower participants to take control of their clinical trial experience, begin a conversation with our experts at http://www.clinone.com.

Share article on social media or email: